|
Unknown Effect
 |
Background
Dr. von Mehren has written an
excellent introduction to for this agent called, "ET-743: A Review of Recent
Results".
Research Results: Ewing's
Sarcoma
-
2002 ASCO
phase 2 results which mention
2/8 ES success; authors are in Italy and
Switzerland
-
Closed COG
pediatric phase 1 trial (Baruchel
at Toronto was the lead)
-
2002 ASCO
abstract on this study
discussing dosing
-
1/1 response
for Ewing's. There was prolonged partial response for a relapsed ES
patient on this trial at dose 1100 mg/m2; the patient
received 16 treatments (one year) and was still responding when she
stopped the drug.
more information
-
2002
abstract stating that ET-743 kills
Ewing's sarcoma cells. Both drug-sensitive and drug-resistant bone tumor
cells were used (note: this is cell line research)
Research Results: Non-Ewing's
Sarcoma
-
On the Phase 1 ET-743+Doxil trial at Fox
Chase, 2/2 sarcomas have become stable;
results not published yet
-
2002 ASCO
phase 2 results, giving
24% partial success rate for soft tissue
sarcomas failing prior chemo; authors are from Memorial Sloan-Kettering
Cancer Center and Dana Farber Cancer Institute
-
Closed
phase 2 trial in Europe (Ewing's
sarcoma NOT allowed)
-
Closed
pediatric phase 2 trial at Memorial Sloan-Kettering Cancer Centefor
osteosarcoma
-
2002
abstract discussing phase 2 trial
results; authors are from Dana Farber Cancer Institute and France; no
discussion on efficacy
|
